Till Wallrabenstein

4PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Oct 23, 2026
Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.

|Jan 17, 2024
Corticosteroid-resistant immune-related adverse events: a systematic review.

Eveline Daetwyler, Till Wallrabenstein, David König

|Oct 28, 2023
Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane-PLD versus PLD-Taxane in Patients with Metastatic Breast Cancer.

Till Wallrabenstein, Anton Oseledchyk, Eveline Daetwyler

|May 06, 2023
Pegylated liposomal doxorubicin (PLD) in daily practice-A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer.

T Wallrabenstein, E Daetwyler, A Oseledchyk

Pageof 1

Frequent Collaborators

2 joint publications

Eveline Daetwyler

1 joint publications

Marcus Vetter

1 joint publications

David König

1 joint publications

Alfred Zippelius